Work

Agonistas del receptor GLP-1 en enfermedades reumáticas inflamatorias: impacto inmunometabólico, obesidad y potencial terapéutico

Year: 2026
Type: article
Abstract: Inflammatory rheumatic diseases (IRDs) are a major cause of disability worldwide and are characterized by persistent immune activation associated with chronic inflammation. In this context, the present study aimed to analyze the therapeutic potential of glucagon-like peptide-1 receptor agonists (GLP-1RAs) in inflammatory rheumatic diseases, with particular emphasis on their immunometabolic effects and their potential benefits for patients with metabolic comorbidities, especially obesity. A literature review was conducted using scientific publications in English and Spanish. The evidence indicates that IRDs share common pathophysiological mechanisms, including loss of immune tolerance, autoantibody production, immune complex formation, and systemic inflammation. In addition, metabolic disorders such as obesity, type 2 diabetes mellitus, and dyslipidemia contribute to a chronic low-grade inflammatory state that exacerbates disease activity and worsens clinical outcomes. The reviewed studies suggest that GLP-1 receptor agonists exert anti-inflammatory and immunometabolic effects that may complement conventional therapies by improving metabolic control and reducing systemic inflammation. Although the available findings are promising, current evidence remains limited. Therefore, well-designed clinical studies with greater methodological rigor are needed to establish the efficacy and safety of GLP-1 receptor agonists as part of the comprehensive management of inflammatory rheumatic diseases.
Language: English
Subfield: Rheumatology
Field: Medicine
Open Access status: diamond
OpenAlex ID: W7204273258
FWCI:
Cites: 23
Cited by:
Related to: 10